FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

	(-)					ion 30(h) of the												•
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT]							eck all applic Directo	ationship of Reporting (all applicable) Director		10% O	vner			
(Last) (First) (Middle) C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200				3. Date of Earliest Transaction (Month/Day/Year) 03/04/2021								below)	Officer (give title Other (specify below) Chief Financial Officer					
(Street) SEATTL	E W	'A	98102		If Amendment, Date of Original Filed (Month/Day/Year)							Line	Y Form f	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			n	
(City)	(S	tate)	(Zip)															
		Tab	le I - Nor	-Deriva	ative Se	curities Ac	quii	red,	Disp	osed o	f, o	r Bene	ficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transc Date (Month/L			action 2A. Deemed Execution Date, if any (Month/Day/Year)			e, Transaction Disposed Of (D Code (Instr. 5)		ties Acquired (A) I Of (D) (Instr. 3, 4			Benefici Owned F	es ally Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
							[Code	v	Amount	mount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	Stock			03/04	/2021			A		20,60	4	A	\$0.00	21,	21,604		D	
		-				urities Acq s, warrants		,		,			•	Owned				
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year)		Date, Tr	ransaction ode (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable Expiration Date (Month/Day/Year)				e and 7. Title and Amof Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Date

Exercisable

(D)

Expiration

03/04/2021

Title

Stock

Explanation of Responses:

\$43.68

1. The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

(A)

51,511

Remarks:

Stock Option

(Right to Buy)

> /s/ Chad Cohen by Eric Billings, Attorney-in-Fact

Amount or Number

Shares

51,511

\$0.00

03/08/2021

51,511

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

03/04/2021

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.